ZYMOGENETICS (NASDAQ:ZGEN)
5.92
+0.18 (3.14%)
| ZYMOGENETICS (NASDAQ:ZGEN) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $5.74 | 52 Week High | $6.71 | ||
| Open | $5.74 | 52 Week Low | $2.06 | ||
| Day High | $5.95 | P/E | N/A | ||
| Day Low | $5.61 | EPS | $-0.95 | ||
| Volume | 175,209 | ||||
| More ZGEN Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| BMY | 11 | PARL | 3 |
| KG | 3 | CPHD | 3 |
| PBH | 3 | HUM | 2 |
| KLAC | 2 | MOVE | 2 |
| FCEL | 2 | NHWK | 2 |
| OCNW | 2 | TARG | 2 |
Entities who have mentioned ZGEN
- Jefferies & Co | View Related Stories »
- Citi | View Related Stories »
- JPMorgan | View Related Stories »
- Deerfield Management | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Morgan Stanley | View Related Stories »
- UBS | View Related Stories »
- Scopia Capital | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Argus | View Related Stories »
- After-Hours Movers | View Related Stories »
- Piper Jaffray | View Related Stories »
- Deutsche Bank | View Related Stories »
- GLG Partners | View Related Stories »
- Trading Radar | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- KeyBanc | View Related Stories »
- Crude Oil | View Related Stories »
- Jesup & Lamont | View Related Stories »
- Twitter | View Related Stories »
- Merrill Lynch | View Related Stories »
- Collins Stewart | View Related Stories »
- Goldman Sachs | View Related Stories »
- Meredith Whitney | View Related Stories »
- Dividend | View Related Stories »
View All Major News StreetInsider.com Major News for ZGEN
- ZymoGenetics (ZGEN) Reports Q3 Loss of $0.17
- ZymoGenetics (ZGEN) Reports Wider-Than-Expected Q2 Loss of $0.39
- ZymoGenetics (ZGEN) Reports Smaller-Than-Expected Q1 Loss
View All ReportsStreetInsider.com Reports on ZGEN
- Morning Movers 11/06: ACLS, CVM, ZIOP, LPSN, CABL, ZGEN Higher; NHWK, GOK, CROX, CVI, RAIL, CSTR Lower
- Wedbush Upgrades ZymoGenetics (ZGEN) to Outperform; Believe ZGEN on Track to Meet 2010 Sales Estimates
- ZymoGenetics (ZGEN) Reports Q3 Loss of $0.17
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- ZymoGenetics (ZGEN) and Bristol-Myers (BMY) Present Phase 1b PEG-Interferon Data for HCV Treatment
View All Press ReleasesCompany Press Releases on ZGEN
- Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com
- ZymoGenetics Reports Third Quarter 2009 Financial Results
- Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C
- ZymoGenetics to Webcast Presentation at Oppenheimer Healthcare Conference
- ZymoGenetics Initiates Phase 2 Clinical Trial of PEG-Interferon lambda in Hepatitis C with Bristol-Myers Squibb
StreetInsider Reports on ZGEN by Category
View All BlogsBlogs on ZGEN
- Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
- Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
- Tuesday's Options Recap
- Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
- ZymoGenetics Inc. Q4 2008 Earnings Call Transcript
View All FilingsSEC Filings on ZGEN
- Form 8-K ZYMOGENETICS INC For: Nov 06
- Form 10-Q ZYMOGENETICS INC For: Sep 30
- Form 8-K ZYMOGENETICS INC For: Nov 05
- Form 8-K ZYMOGENETICS INC For: Nov 02
Comments on recent ZGEN articles
Comments on ZGEN
No comments are currently available.
on Oct 29, 2008
at 12:39 PM atacicept Would you be so kind to let us know what kind of severe infection those patients have presented?
Article: ZymoGenetics (ZGEN) Announces Merck Serono to Discontinue Study in Lupus Nephritis in Ongiong Phase II/III Trials